C4 Therapeutics: An Entry Point If There's Ever Going To Be One

When last I wrote about C4 Therapeutics (NASDAQ: CCCC ) a few months ago , my headline stated that the stock is getting "too cheap to ignore," but this did not ascend toI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure ...